These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32382773)

  • 21. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.
    Mosquera-Orgueira A; Pérez-Encinas M; Hernández-Sánchez A; González-Martínez T; Arellano-Rodrigo E; Martínez-Elicegui J; Villaverde-Ramiro Á; Raya JM; Ayala R; Ferrer-Marín F; Fox ML; Velez P; Mora E; Xicoy B; Mata-Vázquez MI; García-Fortes M; Angona A; Cuevas B; Senín MA; Ramírez-Payer A; Ramírez MJ; Pérez-López R; González de Villambrosía S; Martínez-Valverde C; Gómez-Casares MT; García-Hernández C; Gasior M; Bellosillo B; Steegmann JL; Álvarez-Larrán A; Hernández-Rivas JM; Hernández-Boluda JC
    Hemasphere; 2023 Jan; 7(1):e818. PubMed ID: 36570691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of clinical features and prognosis of primary myelodysplastic syndromes with myelofibrosis patients].
    Su T; Zhang PH; Xu ZF; Chen HS; Qin TJ; Zhang Y; Zhang HL; Fan LW; Pan LJ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):378-82. PubMed ID: 22781796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.
    Samuelson Bannow BT; Salit RB; Storer BE; Stevens EA; Wu D; Yeung C; Fang M; Petersdorf EW; Linenberger ML; Woo J; Sorror ML; Doney K; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):386-392. PubMed ID: 28970176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis.
    Bae E; Park CJ; Cho YU; Seo EJ; Chi HS; Jang S; Lee KH; Lee JH; Lee JH; Suh JJ; Im HJ
    Int J Lab Hematol; 2013 Dec; 35(6):629-36. PubMed ID: 23693053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
    Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
    Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of myelofibrosis.
    Vannucchi AM
    Hematology Am Soc Hematol Educ Program; 2011; 2011():222-30. PubMed ID: 22160038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
    Masarova L; Verstovsek S
    Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.
    Singh N; Sazawal S; Upadhyay A; Chhikara S; Mahapatra M; Saxena R
    Indian J Pathol Microbiol; 2015; 58(2):187-91. PubMed ID: 25885131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myelofibrosis in chronic myeloproliferative disorders--dynamics and clinical impact.
    Thiele J; Kvasnicka HM
    Histol Histopathol; 2006 Dec; 21(12):1367-78. PubMed ID: 16977587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
    Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Idiopathic Myelofibrosis: Clinico-Epidemiological Profile and Risk Stratification in Pakistani Patients.
    Sultan S; Irfan SM
    Asian Pac J Cancer Prev; 2015; 16(18):8629-31. PubMed ID: 26745128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
    Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
    Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.
    Passamonti F; Mora B; Barraco D; Maffioli M
    Curr Hematol Malig Rep; 2018 Jun; 13(3):173-182. PubMed ID: 29713873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
    Bose P; Verstovsek S
    Cancer; 2016 Mar; 122(5):681-92. PubMed ID: 26717494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical features and prognostic analysis of 75 primary myelofibrosis patients].
    Yu Q; Xu L; Gao X; Xu W; Yan H; Wu W; Li J; Shen Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):922-5. PubMed ID: 25339331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired von Willebrand Syndrome During the Course of Myelofibrosis: Analysis of 32 Cases.
    Mital A; Prejzner W; Hellmann A
    Adv Clin Exp Med; 2015; 24(6):1001-6. PubMed ID: 26771972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK.
    Harrison CN; Mead AJ; Drummond MW; Chiu G; Bains R
    Br J Haematol; 2020 Mar; 188(6):e105-e109. PubMed ID: 32077091
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.